| Literature DB >> 22475262 |
Eglal A Abdelaleem1, Nada S Abdelwahab.
Abstract
BACKGROUND: Metronidazole (MET) and Diloxanide Furoate (DF), act as antiprotozoal drugs, in their ternary mixtures with Mebeverine HCl (MEH), an effective antispasmodic drug. This work concerns with the development and validation of two simple, specific and cost effective methods mainly for simultaneous determination of the proposed ternary mixture. In addition, the developed multivariate calibration model has been updated to determine Metronidazole benzoate (METB) in its binary mixture with DF in Dimetrol® suspension.Entities:
Year: 2012 PMID: 22475262 PMCID: PMC3344677 DOI: 10.1186/1752-153X-6-27
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Concentrations of Mebeverine HCl, Diloxanide Furoate and Metronidazole in the calibration and validation sets
| MEH (μg mL-1) | DF (μg mL-1) | MET (μg mL-1) | |
|---|---|---|---|
| 1 | 3 | 11 | 15 |
| 2 | 3 | 7 | 25 |
| 3 | 2 | 15 | 25 |
| 4* | 2 | 11 | 20 |
| 5 | 4 | 15 | 20 |
| 6 | 4 | 13 | 25 |
| 7* | 3 | 13 | 10 |
| 8 | 3.5 | 15 | 15 |
| 9 | 4 | 11 | 10 |
| 10 | 3 | 9 | 20 |
| 11 | 2.5 | 13 | 20 |
| 12 | 3.5 | 13 | 5 |
| 13* | 3.5 | 9 | 10 |
| 14* | 2.5 | 9 | 25 |
| 15 | 2.5 | 7 | 15 |
| 16 | 3.5 | 7 | 20 |
| 17* | 2.5 | 11 | 5 |
| 18 | 2 | 13 | 15 |
| 19 | 3.5 | 11 | 25 |
| 20 | 3 | 15 | 5 |
| 21 | 4 | 7 | 5 |
| 22* | 2.5 | 15 | 10 |
| 23 | 2 | 7 | 20 |
| 24* | 4 | 9 | 15 |
| 25 | 2 | 9 | 5 |
* Samples used for model validation
Figure 1Zero order absorption spectra of 22.5 μg mL.
Figure 2The mean centered second ratio absorption spectra of)a) MEH, (b) DF and (c) MET in methanol.
Regression and analytical parameters of the proposed MCR method for determination of Mebeverine HCl, Diloxanide Furoate and Metronidazole
| Parameters | MCR Method | ||
|---|---|---|---|
| 22.726 | 4.6825 | 1095 | |
| 6.136 | 0.4945 | -6.5508 | |
| 0.9998 | 0.9999 | 0.9999 | |
| 99.13 | 100.12 | 100.50 | |
| 0.991 | 0.879 | 0.799 | |
| 1.205 | 1.003 | 1.220 | |
Determination of the studied drugs in the laboratory prepared mixtures (L.P. M) and tablets by the proposed methods and statistical comparison with the reported method
| Parameters | MCR method | PLS method | ||||
|---|---|---|---|---|---|---|
| 99.91 ± 2.338 | 100.88 ± 2.149 | 102.39 ± 1.780 | 99.85 ± 2.368 | 101.40 ± 1.311 | 100.54 ± 2.194 | |
| 0.063 | 0.200 | 0.459 | ||||
| 98.49 ± 1.419 | 100.15 ± 1.332 | 99.45 ± 1.127 | 99.33 ± 1.329 | 99.44 ± 0.965 | 100.78 ± 1.575 | |
| 99.23 ± 1.122 | 101.50 ± 2.701 | 100.02 ± 1.752 | 102.54 ± 0.638 | 100.00 ± 1.858 | 98.90 ± 0.996 | |
| 10 | 10 | 10 | 10 | 10 | 10 | |
| | ||||||
| | 2.037 | 2.506 | 1.061 | 1.786 | 1.315 | 2.070 |
| | 10 | 10 | 10 | 10 | 10 | 10 |
| 1.905 | 1.137 | 0.376 | 0.755 | 0.758 | 2.007 | |
: Average of 3 determinations
: Average of 6 determinations
: The values in the parenthesis are the corresponding theoretical values at p = 0.05
Figure 3The average spectra of Dimetrol .
RMSEP and percentage recoveries of the updated PLS model at different number of updating samples
| No of updating | DF | METB | ||
|---|---|---|---|---|
| 1 | 0.923 | 1.018 | ||
| 2 | 0.393 | 57.42% | 0.535 | 47.45% |
| 3* | 0.309 | 66.52% | 0.356 | 65.03% |
| 4 | 0.305 | 66.96% | 0.377 | 62.97% |
* The optimum number of updating samples needed
Determination of the studied drugs in Dimetrol® suspension by the updated PLS model and statistical comparison with the reported RP-HPLC method
| Parameters | Updated PLS model | |
|---|---|---|
| 101.19 ± 1.327 | 99.59 ± 0.981 | |
| 99.95 ± 1.233 | 100.55 ± 1.159 | |
| 10 | 10 | |
| 0.738 | 1.026 | |
| 10 | 10 | |
| 0.200 | 0.444 | |
: Average of 6 determinations
: Average of 3 determinations
: The values in the parenthesis are the corresponding theoretical values at p = 0.05